纳络酮联合重组组织型纤溶酶原激活剂治疗急性脑梗死的疗效及安全性评价

目的观察纳络酮联合重组组织型纤溶酶原激活剂（rt-PA）治疗急性脑梗死的临床疗效，并评定其安全性。方法将我院2012年1月-2013年2月间收治的118例急性脑梗死患者随机分为两组各59例，rt—PA组给予rt—PA治疗，联合组在11：～PA组基础上加用纳络酮，比较两组ESS评分、总有效率等。结果联合组治疗后ESS评分和总有效率均显著高于rt—PA组，组间差异显著（P〈0．01）；两组不良反应发生率均较低。结论纳络酮联合rt-PA治疗急性脑梗死疗效显著，安全可靠，值得临床推广应用。

Joint naloxone original recombinant tissue type fibrinolytic enzyme activator in treatment of acute cerebral infarction curative effect and safety evaluation

Objective To observe the joint naloxone original recombinant tissue type fibrinolytic enzyme activator（rt-PA） in treatment of acute cerebral infarction clinical curative effect, and to assess its security. Methods Our hospital from January 2012 to February 2012 between the treated 118 patients with acute cerebral infarction were randomly divided into two grous, rt- PA group 59 patients treatment, joint 59 patients in rt-PA group, naloxone used to drugs on the basis of comparing two groups after treatment of ESS score, total effective rate, and so on and so forth. Results The combined treatment group after ESS scores and total effective rate were significantly higher than that of rt-PA group, two groups are significant difference（P〈0.01）, At the same time two groups of incidence of adverse reactions are lower. Conclusion Combined therapy with rt-PA naloxone in acute cerebral infarction Curative effect significantly, safe and reliable, worthy of clinical popularization and application.